My name is Hugo Peris.

I've lived in San Francisco since 2015. Between 2008 and 2015 I lived in Auckland, Sydney, Chicago and Shanghai. Originally from Barcelona.

Between January 2011 and May 2015 I was responsible for business development at Luqa Pharmaceuticals, a China-based and China-focused specialty pharmaceutical company, where I served on the Board until May 2018. In May 2015, Luqa announced the completion of a Series A financing for US$15M led by Morningside Ventures. In May 2018, Luqa announced the completion of a Series B financing for US$15M led by Cenova Capital.

I also serve as a non-executive member of the Board of Laboratorios SALVAT, a privately-held Spanish pharmaceutical company of which I am part of the 4th generation.

In February 2016 I started Spiral Therapeutics, a clinical stage company developing first-in-class therapeutics for prevention and treatment of hearing loss. In December 2018, Spiral announced the initial closing of a Series A financing co-led by Camden Partners and Savoir Capital, and the beggining of a Phase 1 trial for its lead drug candidate, LPT99.

You can follow me on LinkedIn, Crunchbase and Twitter.